Active Surveillance for Low Risk Prostate Cancer

Active Surveillance Methodology for Low Risk Prostate Cancer

An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.

Inclusion Criteria:

• prostate adenocarcinoma verified by at least 12 core biopsy
• patient must understand the sense of research, agree to participate and sign a form of agreement
• low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA<10 ng/ml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)
• not more than 33% cores with adenocarcinoma

Exclusion Criteria:

• previous treatment of prostate cancer
• other prostatic malignant neoplasms
• other oncological diseases
• treatment with 5-alfa-reductase inhibitors
• patient's refuse to continue study
• patient's desire to begin treatment